e03015f06f
- Source: inbox/queue/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
71 lines
No EOL
3 KiB
Markdown
71 lines
No EOL
3 KiB
Markdown
---
|
|
type: entity
|
|
entity_type: research_program
|
|
name: Texas IMPACT Consortium
|
|
full_name: Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma
|
|
domain: health
|
|
status: active
|
|
founded: 2025-12
|
|
headquarters: Texas, USA
|
|
website: null
|
|
tags: [ibogaine, OUD, PTSD, TBI, psychedelic, clinical-trial, Texas]
|
|
---
|
|
|
|
## Overview
|
|
|
|
The Texas IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma) Consortium represents the largest state-sponsored psychedelic research investment in US history, with $50 million from Texas Health and Human Services Commission plus up to $50 million ARPA-H federal match for a potential $100 million total.
|
|
|
|
## Structure
|
|
|
|
**Lead institutions:** UTHealth Houston and UTMB Health (Galveston)
|
|
|
|
**Consortium members (11 institutions):**
|
|
- UTHealth Houston
|
|
- UTMB Health
|
|
- Texas Tech University
|
|
- Texas Tech UTHS El Paso
|
|
- UT Austin
|
|
- UT Health Science Center San Antonio
|
|
- UT Tyler
|
|
- UT Rio Grande Valley
|
|
- Texas A&M University
|
|
- University of North Texas Health Science Center
|
|
- Baylor College of Medicine
|
|
- JPS Health Network (Dallas)
|
|
|
|
## Research Design
|
|
|
|
**Duration:** Two-year multicenter trial (Phase 2 scale)
|
|
|
|
**Conditions targeted:**
|
|
- Opioid use disorder (primary indication) — UTHealth Houston + UTMB
|
|
- Traumatic brain injury — UT Austin + Baylor College of Medicine
|
|
- PTSD — coordinated across sites
|
|
|
|
**Key evidence basis:**
|
|
- Stanford 2024 study (n=30 veterans): 88% PTSD reduction, 87% depression reduction at 1 month
|
|
- MAPS Phase 2 OUD: 70-75% abstinence at 1 month
|
|
- Mechanism: Opioid receptor reset + GDNF production → dopaminergic neuron regeneration
|
|
- Unique capability: Abolishes opioid withdrawal symptoms within 1-2 days
|
|
|
|
## Regulatory Context
|
|
|
|
**Current status:** Ibogaine is Schedule I (federal) with no completed Phase 3 trial in US
|
|
|
|
**Safety barrier:** QT prolongation risk with >30 documented deaths in unsupervised settings
|
|
|
|
**Political support:**
|
|
- Texas SB 2308 (December 2025): Authorized $50M state funding
|
|
- Trump EO (April 2026): Directed ARPA-H funding toward ibogaine for veterans; DEA to initiate rescheduling upon Phase 3 completion
|
|
- Colorado Proposition 122: Decriminalized in Colorado
|
|
|
|
## Timeline
|
|
|
|
- **2025-12** — Texas SB 2308 authorizes $50M state funding for IMPACT consortium
|
|
- **2026-04** — Trump executive order directs ARPA-H to provide up to $50M federal match and commits DEA to rescheduling process upon Phase 3 completion
|
|
|
|
## Significance
|
|
|
|
The Texas IMPACT consortium addresses the opioid overdose crisis (79,384 deaths in 2024), the most acute public health emergency in mental health/substance use. Ibogaine is the only psychedelic with credible single-session evidence for OUD specifically. The program demonstrates bipartisan political support through veteran-focused framing, with conservative Texas authorizing the largest state psychedelic research investment in US history.
|
|
|
|
Realistic FDA approval timeline: 2029-2030 if Phase 2 data supports Phase 3 advancement, making ibogaine 4-5 years behind psilocybin despite addressing higher-mortality condition. |